After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis as a treatment for a type of lung cancer. The US regulator cleared Emrelis ...

Citizen’s reputation as Seiko’s sidekick in Japanese watchmaking is undeserved. The brand is a worthy adversary in many respects, offering a balanced alternative to its horological neighbor, and often ...

As converter technology improves, so does the demand to resolve very high intermediate frequencies (IFs) accurately at high speeds. This poses two challenges: the converter design itself and the front ...

Gender disparities in metastatic RCC therapies and outcomes. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full text component.